EnXray Appooints Robert Barlow as CEO
1 October, 2017, Liverpool, UK – EnXray Ltd is pleased to announce the appointment of Robert Barlow to the role of CEO. Robert, who joined the company in May 2017 as Commercial Director, will lead the commercialisation activities of EnXray's Low Energy X-ray (LEXR) technology, building on his 25 years experience in commercial sales & marketing in the healthcare and medical device industry. Before joining EnXray, Robert worked at Covidien (now Medtronic) as well as with venture capital backed start-ups (e.g. Lynton Lasers and Microsulis Medical).
Notes to editors
About EnXray Limited
EnXray Limited (EnXray) is a development-stage technology company founded in 2012, focused on commercializing its proprietary Low Energy X-rays (LEXR) technology for use in sterilization. EnXray’s first target market is the medical device manufacturing industry, where our technology will enable companies to manage and control the sterilization of their products (the final critical step of their production process) on-site & on-demand, providing significant benefits to its customers.
Today, the global medical device manufacturing industry relies upon large scale remote sterilization facilities, which creates significant logistics issues for manufacturers, as well as their end customers, such as hospitals and the NHS.
LEXR, or “soft x-rays” are a form of ionizing radiation in the range of 5 – 20 keV, which have some compelling characteristics, including a short transmission range through air, combined with a high absorption coefficient, which makes it a very efficient method for delivering high dosages of radiation in a relatively short period of time, without the need for extensive shielding. This is different from gamma-irradiation, where products have to be paletted in order to get reasonable sterilization efficacy, LEXR is designed for end-of-line processing and sterilization of individual products.